Pandemic Diseases are infectious diseases that spread rapidly across multiple countries and continents, affecting a large number of people worldwide. These diseases pose significant threats to public health, economies, and social stability, highlighting the importance of effective prevention and control measures, including vaccines. Throughout history, pandemics have been caused by various pathogens, including viruses, bacteria, and other infectious agents. Some of the most notable pandemic diseases include the Spanish flu of 1918, which killed millions of people worldwide, and the more recent COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2.
Vaccines play a crucial role in preventing and controlling pandemic diseases by stimulating the immune system to recognize and neutralize the infectious agent. Vaccines work by introducing a harmless form of the pathogen or its components into the body, prompting the immune system to produce antibodies and memory cells that provide protection against future infections. During pandemics, the development and deployment of vaccines are prioritized to halt the spread of the disease and mitigate its impact on public health. Vaccine development efforts may be accelerated through emergency authorization processes, allowing vaccines to be made available to the population more quickly.
In the case of the COVID-19 pandemic, multiple vaccines were developed in record time using innovative technologies such as mRNA vaccines. Vaccination campaigns have played a crucial role in controlling the spread of the virus, reducing illness, hospitalizations, and deaths, and facilitating the reopening of economies and societies. However, challenges remain in ensuring equitable access to vaccines during pandemics, particularly for low- and middle-income countries. Global cooperation and solidarity are essential for ensuring that vaccines reach all populations, regardless of socioeconomic status or geographical location.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States